These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 30106659

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD, Levy MC, Schwab GG, Paik Y.
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract] [Full Text] [Related]

  • 3. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A, Carome MA.
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract] [Full Text] [Related]

  • 4. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C, Redish MH.
    Am J Law Med; 2011 Sep; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J.
    Seton Hall Law Rev; 2013 Sep; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract] [Full Text] [Related]

  • 9. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan; 20(112):25. PubMed ID: 21462792
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluating promotional claims as false or misleading.
    Brushwood DB, Knox CA, Liu W, Jenkins KA.
    Am J Health Syst Pharm; 2013 Nov 01; 70(21):1941-4. PubMed ID: 24128969
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L.
    Am J Law Med; 2014 Nov 01; 40(1):141-63. PubMed ID: 24844045
    [No Abstract] [Full Text] [Related]

  • 14. GlaxoSmithKline is fined record $3bn in US.
    Roehr B.
    BMJ; 2012 Jul 03; 345():e4568. PubMed ID: 22761252
    [No Abstract] [Full Text] [Related]

  • 15. When Does FDAMA Section 114 Apply? Ten Case Studies.
    Neumann PJ, Saret CJ.
    Value Health; 2015 Jul 03; 18(5):682-9. PubMed ID: 26297097
    [Abstract] [Full Text] [Related]

  • 16. The commercial speech doctrine in health regulation: the clash between the public interest in a robust First Amendment and the public interest in effective protection from harm.
    Orentlicher D.
    Am J Law Med; 2011 Jul 03; 37(2-3):299-314. PubMed ID: 21847883
    [No Abstract] [Full Text] [Related]

  • 17. Defining "True and Non-Misleading" for Pharmaceutical Promotion.
    Hey SP, Kesselheim AS.
    J Law Med Ethics; 2018 Jun 03; 46(2):552-554. PubMed ID: 30146990
    [No Abstract] [Full Text] [Related]

  • 18. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK, Liang BA.
    Mayo Clin Proc; 2016 Jun 03; 91(6):701-6. PubMed ID: 27084416
    [No Abstract] [Full Text] [Related]

  • 19. Certification denied in pharmaceutical class action.
    Boudreau A, Tombs A.
    Health Law Can; 2012 Aug 03; 33(1):1-4. PubMed ID: 23097924
    [No Abstract] [Full Text] [Related]

  • 20. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA.
    Issue Brief Health Policy Track Serv; 2010 Jan 04; ():1-31. PubMed ID: 20217914
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.